Tubulysin analogs and methods for their preparation
申请人:PFIZER INC.
公开号:US10723727B2
公开(公告)日:2020-07-28
The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
本发明涉及新型细胞毒性管胞素类似物和衍生物、其抗体药物共轭物以及用其治疗包括癌症在内的病症的方法。
[EN] TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION<br/>[FR] ANALOGUES DE LA TUBULYSINE ET LEURS PROCÉDÉS DE PRÉPARATION
申请人:PFIZER
公开号:WO2017134547A1
公开(公告)日:2017-08-10
The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
The first totalsynthesis of tubulysin B is described. The aziridine route to tubuphenylalanine (Tup) of the tubulysin D/U-series could not be transferred to the synthesis of tubutyrosine (blue moiety). Therefore, tubutyrosine (Tut) was synthesized by a Wittig olefination/diastereoselective catalytic reduction sequence. Interestingly, the C-2 epimer of tubulysin B has a cytotoxic activity almost identical